Ceryvyn Therapeutics (ASX:CYV) 1-Year Sharpe Ratio: -1.05 (As of Jul. 11, 2026)


What is Ceryvyn Therapeutics 1-Year Sharpe Ratio?

Ceryvyn Therapeutics ASX:CYV -7.69% 1-Year Sharpe Ratio is -1.05 as of Jul. 11, 2026. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-11), Ceryvyn Therapeutics's 1-Year Sharpe Ratio is -1.05.

Ceryvyn Therapeutics  (ASX:CYV) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Ceryvyn Therapeutics 1-Year Sharpe Ratio Related Terms

ASX:CYV vs VRTX, REGN, ALNY: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's 1-Year Sharpe Ratio falls into.


Ceryvyn Therapeutics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -1.05 mean?
Ceryvyn Therapeutics (ASX:CYV) has a 1-Year Sharpe Ratio of -1.05 as of Jul. 11, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' 1-Year Sharpe Ratio too high?
Ceryvyn Therapeutics' current 1-Year Sharpe Ratio is -1.05.
How does Ceryvyn Therapeutics' 1-Year Sharpe Ratio compare to VRTX and REGN?
Ceryvyn Therapeutics' 1-Year Sharpe Ratio of -1.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current 1-Year Sharpe Ratio is -1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current 1-Year Sharpe Ratio of -1.05. The current 1-Year Sharpe Ratio is -1.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current 1-Year Sharpe Ratio is -1.05 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.